Literature DB >> 19687521

Evaluation of endocrine tests. D: the prolonged fasting test for insulinoma.

A C van Bon1, N Benhadi, E Endert, E Fliers, W M Wiersinga.   

Abstract

OBJECTIVE: To establish the diagnostic performance of the prolonged fasting test in patients suspected of insulinoma.
METHODS: We included all patients who were referred to our department between August 1995 and August 2006 with a clinical suspicion of insulinoma. Insulinoma was diagnosed by a positive Whipple's triad during the prolonged fast in combination with an insulin/C-peptide ratio below 1. The presence of insulinoma was confirmed by histopathological data, which was considered the golden standard. If the prolonged fast was negative, long-term follow-up was obtained.
RESULTS: Ten patients had a positive Whipple's triad during the prolonged fast: eight had a histologically proven insulinoma, and two had factitious hypoglycaemia (insulin/C-peptide ratio >1.0) One additional patient likely had an insulinoma, but the Whipple's triad remained absent at up to 56 hours of fasting. Follow-up (median 53 months (3 to 142) in 76% of patients with a negative fasting test revealed no missed cases of insulinoma. During the prolonged fast the glucose, insulin and C-peptide concentrations overlapped in patients with and without insulinoma.
CONCLUSION: In our centre, the prolonged fasting test defined as a positive Whipple's triad in combination with an insulin/C-peptide ratio <1 had a sensitivity of 88.9% and a specificity of 100% for the diagnosis of insulinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687521

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  7 in total

Review 1.  Diagnosis and management of insulinoma.

Authors:  Takehiro Okabayashi; Yasuo Shima; Tatsuaki Sumiyoshi; Akihito Kozuki; Satoshi Ito; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

2.  Concurrent insulinoma and impaired glucose tolerance suspected as owing to obesity.

Authors:  Katsumi Iizuka; Taro Fujisawa; Jun Takeda
Journal:  BMJ Case Rep       Date:  2016-01-04

3.  Re-occurrence of pancreatic insulinoma: an usual cause of hypoglycaemia.

Authors:  Charles Anwuzia-Iwegbu; Kaniseya Nadarasa; William Drake
Journal:  BMJ Case Rep       Date:  2013-02-01

4.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.

Authors:  Robert T Jensen; Guillaume Cadiot; Maria L Brandi; Wouter W de Herder; Gregory Kaltsas; Paul Komminoth; Jean-Yves Scoazec; Ramon Salazar; Alain Sauvanet; Reza Kianmanesh
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

5.  Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franco Grimaldi; Nicola Fazio; Roberto Attanasio; Andrea Frasoldati; Enrico Papini; Francesco Angelini; Roberto Baldelli; Debora Berretti; Sara Bianchetti; Giancarlo Bizzarri; Marco Caputo; Roberto Castello; Nadia Cremonini; Anna Crescenzi; Maria Vittoria Davì; Angela Valentina D'Elia; Antongiulio Faggiano; Stefano Pizzolitto; Annibale Versari; Michele Zini; Guido Rindi; Kjell Oberg
Journal:  J Endocrinol Invest       Date:  2014-07-20       Impact factor: 4.256

6.  A case of low serum insulin levels in a patient with insulinoma.

Authors:  Chun-Han Lo; Ding-Ping Sun
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-08-16

7.  Smarter Modeling to Enable a Smarter Insulin.

Authors:  Simeon I Taylor; Richard D DiMarchi
Journal:  Diabetes       Date:  2020-08       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.